Hippocratic AI
Hippocratic AI develops AI agents for non-diagnostic, patient-facing healthcare tasks such as appointment follow-ups and care outreach.
The Company
Hippocratic AI was founded by Munjal Shah and focuses on AI agents for patient-facing tasks that do not involve diagnosis, such as follow-up calls and care reminders. It says its agents have handled more than 115 million patient interactions with no reported safety issues.
In November 2025 Hippocratic AI raised a $126 million Series C led by Avenir Growth, with CapitalG, General Catalyst, a16z and Kleiner Perkins participating, at a $3.5 billion valuation, up from $1.64 billion in January 2025. It has more than 50 health-system, payer and pharma customers across six countries.
Why It Matters
Hippocratic AI is a leading test of AI agents in direct contact with patients, a high-stakes use where safety and regulation matter most.
Valuation History
- $1.64B→Jan 2025$141M Series B
- $3.5B→Nov 2025$126M Series C
What Changed
Hippocratic AI is founded.
A $141M Series B values it at $1.64B.
A $126M Series C values it at $3.5B.
THE NEXT COMPANY. A CLEARER PICTURE.
Get the next breakdown.
Independent company research and perspectives on private markets, delivered through The Private Ledger on Substack.